SAMe treatment study for alcoholic cirrhosis
Part of Digestive system clinical trials.
This Phase 2 study tests whether SAMe can help people with alcoholic cirrhosis (scarred liver) who are in early to mid stages. It may also include healthy volunteers to compare safety and blood/body measurements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 70 years old (study includes this age range)
- You have cirrhosis (scarred liver) linked to alcohol use, confirmed by scan/biopsy or FibroScan
- Your liver function is in Child Class A or B when you enroll
- No recent serious alcohol use for healthy volunteers (patients may still drink, but controls must not)
- You do not have active infections (like pneumonia or positive blood/urine cultures)
- No hepatitis B, hepatitis C, or HIV, and no pregnancy or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic differences in people with alcohol-related liver illness, including a recent jaundice episode (alcoholic hepatitis). By following people over time, it may help doctors better predict illness and understand why some people develop worse liver problems.
This Phase 3 trial tests whether a cell medicine called Cellgram-LC, delivered through a catheter into the liver artery, is safer and works better for people with alcoholic cirrhosis. It may help improve outcomes in people with more advanced liver scarring.
This Phase 2 trial tests whether rosuvastatin (a cholesterol-lowering medicine) can improve how well the liver functions and slow worsening scarring in people with cirrhosis. It also checks for side effects and safety.
This trial tests if a supplement called SAMe can help prevent liver cancer in people with cirrhosis caused by MASLD (a fatty liver disease linked to metabolic issues). If you have MASLD, cirrhosis, and certain risk factors like diabetes or high blood pressure, you may be able to join.
This early-phase study is testing a treatment approach for people with alcoholic hepatitis (liver inflammation caused by heavy alcohol use). It may help by improving liver function and outcomes in people who meet specific lab and health criteria.
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Hear when a new Alcoholic Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.